Loading...
Loading...
SIOX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 25.4M |
| Operating I/L | -25.4M |
| Other Income/Expense | -0.1M |
| Interest Income | 0.0M |
| Pretax | -25.5M |
| Income Tax Expense | -0.1M |
| Net Income/Loss | -25.5M |
Sio Gene Therapies Inc. is a clinical-stage company specializing in the development of gene therapies for neurodegenerative diseases. Through its license agreements with Oxford BioMedica (UK) Ltd. and The University of Massachusetts Medical School, the company is focused on developing and commercializing gene therapy products such as AXO-Lenti-PD, AXO-AAV-GM1, and AXO-AAV-GM. These gene therapy products aim to transform the lives of patients with neurodegenerative diseases. Sio Gene Therapies Inc. generates revenue through the development and commercialization of these gene therapy products, offering potential treatments for individuals suffering from these debilitating conditions.
